Skip to main content
Clinical Trials/JPRN-UMIN000051151
JPRN-UMIN000051151
Not yet recruiting
未知

Incidence and risk factors of serious infection in neuromyelitis optica spectrum disorders (NMOSD) patients: a retrospective cohort study using Medical Data Vision (MDV) database - Incidence and risk factors of serious infection in neuromyelitis optica spectrum disorders (NMOSD) patients: a retrospective cohort study using Medical Data Vision (MDV) database

Chugai Pharmaceutical Co., Ltd.0 sites4,000 target enrollmentJune 1, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
euromyelitis optica spectrum disorders (NMOSD)
Sponsor
Chugai Pharmaceutical Co., Ltd.
Enrollment
4000
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2023
End Date
October 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The patients who have any record of prescription for the following drugs for the treatment of multiple sclerosis (MS) at any time point: \- Interferon beta\-1a, \- Interferon beta\-1b, \- Ofatumumab, \- Natalizumab, \- Glatiramer acetate, \- Dimethyl fumarate, \- Siponimod fumarate, \- Fingolimod hydrochloride.

Outcomes

Primary Outcomes

Not specified

Similar Trials